RDIF, Hetero agree to produce over 100 mn doses of Sputnik V vaccine in India

Russian Direct Investment Fund (RDIF) and pharma firm Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, Russia's sovereign wealth fund said in a statement.

The parties intend to start the production of Sputnik V at the beginning of 2021, it added.

Currently Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela and other countries. Phase II-III trials are taking place in India, RDIF said.